Envestnet Portfolio Solutions Inc. Has $274,000 Position in Avantor, Inc. (NYSE:AVTR)

Envestnet Portfolio Solutions Inc. lessened its position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 57.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,901 shares of the company's stock after selling 22,804 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Avantor were worth $274,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dodge & Cox lifted its position in shares of Avantor by 44.9% during the fourth quarter. Dodge & Cox now owns 99,145,770 shares of the company's stock worth $2,089,001,000 after purchasing an additional 30,727,673 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Avantor by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 63,969,754 shares of the company's stock worth $1,347,843,000 after buying an additional 1,211,418 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its position in Avantor by 41.4% in the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 30,528,092 shares of the company's stock valued at $643,227,000 after buying an additional 8,936,879 shares during the last quarter. Canada Pension Plan Investment Board grew its stake in shares of Avantor by 0.5% during the fourth quarter. Canada Pension Plan Investment Board now owns 21,037,089 shares of the company's stock valued at $443,251,000 after acquiring an additional 112,644 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Avantor by 2.5% during the fourth quarter. Janus Henderson Group PLC now owns 18,136,206 shares of the company's stock worth $382,131,000 after acquiring an additional 443,501 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AVTR. Cowen downgraded Avantor from a "buy" rating to a "hold" rating in a report on Monday, April 28th. Morgan Stanley lowered Avantor from an "overweight" rating to an "equal weight" rating in a research report on Tuesday, April 29th. TD Cowen cut Avantor from a "buy" rating to a "hold" rating and set a $15.50 target price for the company. in a research note on Monday, April 28th. Royal Bank Of Canada dropped their price target on shares of Avantor from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Monday, April 28th. Finally, The Goldman Sachs Group cut shares of Avantor from a "buy" rating to a "neutral" rating and cut their price target for the company from $23.00 to $14.00 in a report on Tuesday, April 29th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $18.14.

Avantor Price Performance

Shares of Avantor stock traded down $0.01 during trading on Thursday, hitting $13.88. The stock had a trading volume of 6,225,573 shares, compared to its average volume of 8,394,696. The business has a fifty day moving average of $13.14 and a two-hundred day moving average of $16.72. The firm has a market cap of $9.46 billion, a P/E ratio of 13.35, a PEG ratio of 1.48 and a beta of 1.05. Avantor, Inc. has a fifty-two week low of $11.82 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.12 and a quick ratio of 0.75.

Avantor (NYSE:AVTR - Get Free Report) last issued its quarterly earnings results on Friday, April 25th. The company reported $0.23 earnings per share for the quarter, meeting analysts' consensus estimates of $0.23. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a net margin of 10.70% and a return on equity of 11.93%. Avantor's revenue was down 5.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.22 EPS. On average, sell-side analysts expect that Avantor, Inc. will post 1.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Avantor

In other news, Director Gregory L. Summe purchased 30,000 shares of Avantor stock in a transaction that occurred on Friday, May 23rd. The stock was acquired at an average price of $12.50 per share, for a total transaction of $375,000.00. Following the transaction, the director owned 100,000 shares in the company, valued at $1,250,000. The trade was a 42.86% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Joseph R. Massaro acquired 8,100 shares of the firm's stock in a transaction that occurred on Tuesday, April 29th. The stock was purchased at an average cost of $12.30 per share, with a total value of $99,630.00. Following the purchase, the director directly owned 35,038 shares in the company, valued at approximately $430,967.40. This trade represents a 30.07% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 83,100 shares of company stock valued at $1,027,630. Corporate insiders own 1.20% of the company's stock.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.